Table 3.
List of the top 50 target genes determined by ChIP sequencing
| No | Strand | Transcript ID | Symbol | Reference (Coexpression with HER2) |
|---|---|---|---|---|
| 1 | - | NM_001257408 | IKZF3 | Clin Transl Oncol 2020, 22(4):576–584 |
| 2 | + | NM_001005862 | ERBB2 | |
| 3 | + | NM_005310 | GRB7 |
Nature 2000, 406:747–752 J Clin Oncol 2020, 38(5):462–471 Ann Oncol 2020, 31(suppl_4): S1052-S1064 |
| 4 | - | NM_001291726 | PGAP3 |
Breast Cancer Res Treat 2018, 172(2):313–326 Ann Oncol 2020, 31(suppl_4): S1052-S1064 |
| 5 | + | NR_003594.7 | REXO1L2P | |
| 6 | + | NM_032192 | PPP1R1B |
Cancer Res 2012, 72(17):4504–1 Clin Cancer Res 2018, 24(5):1216–1226.4 |
| 7 | - | NM_000723 | CACNB1 | Front Pharmacol 2018, 3;9:861 |
| 8 | - | NM_001025253 | TPD52 | Mol Carcinog 2014, 53(10):807–19 |
| 9 | - | NM_003600 | AURKA |
BMC Cancer 2012, 12:562 JAMA Oncol 2017, 3(5):666–671 |
| 10 | + | NM_001283024 | WDYHV1 | |
| 11 | + | NM_0007591 | CSF3 | |
| 12 | + | NM_001283012 | DEPTOR | |
| 13 | - | NM_000791 | DHFR | |
| 14 | + | NM_001278645 | NDUFB9 | |
| 15 | - | NM_000318 | PEX2 | |
| 16 | + | NM_001011720 | XKR9 | |
| 17 | - | NM_001017926 | ZHX1 | |
| 18 | + | NM_001033521 | CSTF1 | |
| 19 | - | NM_001002796 | MCTP1 | |
| 20 | - | NM_020405 | PLXDC1 | |
| 21 | + | NR_003367 | PVT1 | |
| 22 | + | NM_001165937 | STARD3 |
Nature 2000, 406:747–752 Ann Oncol 2020, 31(suppl_4): S1052-S1064 |
| 23 | - | NM_001146160 | TATDN1 | Oncotarget 2016, 7(14):18,219–28 |
| 24 | + | NM_001277145 | ZBTB10 | |
| 25 | + | NM_015083 | CDK12 |
Nature 2016, 534(7605):55–62 Nucleic Acids Res 2017,45(11):6698–6716 |
| 26 | - | NM_001134671 | DERL1 | |
| 27 | + | NM_032899 | FAM83A | PLoS One 2017, 12(5):e0176778 |
| 28 | - | NM_001184906 | FBXL20 | |
| 29 | - | NM_001242463 | FBXO32 | |
| 30 | + | NM_052886 | MAL2 | |
| 31 | + | NR_039881 | MIR4728 |
Cancer Biomark 2015, 15:807–814 Mol Genet Genomics 2019, 294(1):95–110 |
| 32 | - | NM_138463 | TLCD1 | |
| 33 | - | NM_001308225 | ZNF521 | |
| 34 | + | NM_198844 | ZPBP2 | |
| 35 | - | NM_003657 | BCAS1 | |
| 36 | + | NM_001254 | CDC6 | Endocr Relat Cancer 2006, 13(1):39–49 |
| 37 | + | NM_001359 | DECR1 | |
| 38 | - | NM_032339 | MIEN1 | Oncotarget 2017, 8(54):92,209–92226 |
| 39 | - | NR_039913 | MIR4756 | |
| 40 | - | NR_031608 | MIR663B | |
| 41 | - | NR_107045 | MIR8078 | |
| 42 | + | NM_002439 | MSH3 | |
| 43 | - | NM_001190470 | MTRNR2L2 | |
| 44 | - | NM_006540 | NCOA2 | |
| 45 | + | NM_178170 | NEK8 | |
| 46 | - | NM_139280 | ORMDL3 | |
| 47 | - | NM_173825 | RABL3 | |
| 48 | + | NM_000981 | RPL19 |
Cancer Res 2003, 63(9):2194–9 Oncol Rep 2012, 28(1):365–9 |
| 49 | - | NM_198993 | STAC2 | |
| 50 | + | NR_033770 | ROCK1P1 |
The results showed the 50 most frequently analyzed HAP binding sites and their corresponding target genes by ChIP sequencing